Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders
- PMID: 12851867
- DOI: 10.1016/s0016-5085(03)00669-3
Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders
Abstract
Background & aims: Studies of antidepressants and psychological treatments in functional bowel disorders (FBD) are methodologically limited. The aim of this study was to assess the clinical efficacy and safety of cognitive-behavioral therapy (CBT) against education (EDU) and desipramine (DES) against placebo (PLA) in female patients with moderate to severe FBD (irritable bowel syndrome, functional abdominal pain, painful constipation, and unspecified FBD). We also evaluated the amenability of clinically meaningful subgroups to these treatments.
Methods: This randomized, comparator-controlled, multicenter trial enrolled 431 adults from the University of North Carolina and the University of Toronto with moderate to severe symptoms of FBD. Participants received psychological (CBT vs. EDU) or antidepressant (DES vs. PLA) treatment for 12 weeks. Clinical, physiologic, and psychosocial assessments were performed before and at the end of treatment.
Results: The intention-to-treat analysis showed CBT as significantly more effective than EDU (P = 0.0001; responder rate, 70% CBT vs. 37% EDU; number needed to treat [NNT ], 3.1). DES did not show significant benefit over PLA in the intention-to-treat analysis (P = 0.16; responder rate, 60% DES vs. 47% PLA; NNT, 8.1) but did show a statistically significant benefit in the per-protocol analysis (P = 0.01; responder rate, 73% DES vs. 49% PLA; NNT, 5.2), especially when participants with nondetectable blood levels of DES were excluded (P = 0.002). Improvement was best gauged by satisfaction with treatment. Subgroup analyses showed that DES was beneficial over PLA for moderate more than severe symptoms, abuse history, no depression, and diarrhea-predominant symptoms; CBT was beneficial over EDU for all subgroups except for depression.
Conclusions: For female patients with moderate to severe FBD, CBT is effective and DES may be effective when taken adequately. Certain clinical subgroups are more or less amenable to these treatments.
Comment in
-
Managing functional bowel disorders from the top down: lessons from a well-designed treatment trial.Gastroenterology. 2003 Jul;125(1):249-53. doi: 10.1016/s0016-5085(03)00808-4. Gastroenterology. 2003. PMID: 12851889 Review. No abstract available.
Similar articles
-
Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage.Am J Gastroenterol. 2005 Mar;100(3):664-71. doi: 10.1111/j.1572-0241.2005.30375.x. Am J Gastroenterol. 2005. PMID: 15743366
-
Cognitive factors affect treatment response to medical and psychological treatments in functional bowel disorders.Am J Gastroenterol. 2010 Jun;105(6):1397-406. doi: 10.1038/ajg.2009.748. Epub 2010 Jan 19. Am J Gastroenterol. 2010. PMID: 20087332 Clinical Trial.
-
Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment.Am J Gastroenterol. 2007 Jul;102(7):1442-53. doi: 10.1111/j.1572-0241.2007.01283.x. Epub 2007 May 17. Am J Gastroenterol. 2007. PMID: 17509027 Clinical Trial.
-
Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.Clin Gastroenterol Hepatol. 2013 Sep;11(9):1084-1092.e3; quiz e68. doi: 10.1016/j.cgh.2013.04.032. Epub 2013 May 2. Clin Gastroenterol Hepatol. 2013. PMID: 23644388
-
Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.Drugs. 2003;63(11):1101-20. doi: 10.2165/00003495-200363110-00013. Drugs. 2003. PMID: 12749744 Review.
Cited by
-
[Psychopharmacological treatment in patients with somatoform disorders and functional body syndromes].Nervenarzt. 2012 Sep;83(9):1128-41. doi: 10.1007/s00115-011-3446-9. Nervenarzt. 2012. PMID: 22895795 German.
-
Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT.Health Technol Assess. 2024 Oct;28(66):1-161. doi: 10.3310/BFCR7986. Health Technol Assess. 2024. PMID: 39397570 Free PMC article. Clinical Trial.
-
A randomized clinical trial of metacognitive therapy and nortriptyline for anxiety, depression, and difficulties in emotion regulation of patients with functional dyspepsia.Res Psychother. 2020 Sep 17;23(2):448. doi: 10.4081/ripppo.2020.448. eCollection 2020 Sep 7. Res Psychother. 2020. PMID: 33024721 Free PMC article.
-
Review of the treatment options for chronic constipation.MedGenMed. 2007 May 2;9(2):25. MedGenMed. 2007. PMID: 17955081 Free PMC article. Review.
-
Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment.Can J Gastroenterol. 2007 Apr;21 Suppl B(Suppl B):3B-22B. Can J Gastroenterol. 2007. PMID: 17464377 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical